Online inquiry

IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6733MR)

This product GTTS-WQ6733MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6733MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10815MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA M7824
GTTS-WQ2139MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALD-403
GTTS-WQ14443MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ12037MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ13578MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA QAX-576
GTTS-WQ7440MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GBR500
GTTS-WQ8464MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ2154MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ALD-518
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW